As the primary factors for the reduced anticancer effect 1) the reduced delivery and uptake of the anticancer agent, 2) the need for the conversion of molecular oxygen (O 2 ) into reactive oxygen species (ROS), 3) the preferred therapeutic effect against highly proliferating cells, which is reduced under hypoxic conditions, or 4) adaptation of the cancer cells by promoting cell survival and upregulating certain resistance pathways, has been suggested 1,2,3,4,5
This review is also significant because it positions GHK-Cu in the context of gene data from the Broad Institute's Connectivity Map the same database used by pharmaceutical researchers to discover new drug applications
Glutathione and signal transduction in the mammalian CNS
CD45+ CD33lowCD11bdim myeloid-derived suppressor cells suppress CD8 + T cell activity via the IL-6/IL-8-arginase I axis in human gastric cancer
But using the EFA supplementation, you can correct for that metabolic dysfunction